Results 21 to 30 of about 1,282,511 (265)

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

NEJM Evidence, 2023
Avapritinib in Indolent Systemic MastocytosisIn a randomized trial, patients with indolent systemic mastocytosis were treated with avapritinib or placebo along with supportive care.
J. Gotlib, M. Castells, H. Elberink, F. Siebenhaar, Karin Hartmann, S. Broesby‐Olsen, T. George, J. Panse, Iván Álvarez-Twose, D. Radia, T. Tashi, Christina Bulai Livideanu, V. Sabato, M. Heaney, P. V. van Daele, Sonia Cerquozzi, I. Dybedal, A. Reiter, T. Pongdee, S. Barete, C. Ustun, L. Schwartz, Brant R. Ward, P. Schafhausen, P. Vadas, P. Bose, D. DeAngelo, L. Rein, P. Vachhani, M. Triggiani, P. Bonadonna, Mark Rafferty, N. Butt, S. Oh, Friederike Wortmann, J. Ungerstedt, M. Guilarte, M. Taparia, A. Kuykendall, Cecilia Arana Yi, P. Ogbogu, C. Gaudy-Marqueste, M. Mattsson, William Shomali, M. Giannetti, I. Bidollari, Hui-Min Lin, Erin Sulllivan, B. Mar, R. Scherber, M. Roche, C. Akin, M. Maurer   +52 more
semanticscholar   +1 more source

Targeted therapy for advanced forms of systemic mastocytosis in real clinical practice

Онкогематология, 2023
Background. Mastocytosis is a heterogeneous group of diseases that are characterized by excessive proliferation and accumulation of clonal (neoplastic) mast cells in one or more organs.
D. I. Shikhbabaeva, O. Yu. Vinogradova, A. L. Neverova, M. M. Pankrashkina, M. V. Chernikov, E. O. Detkina, Yu. N. Kobzev, S. G. Malakho, V. V. Ptushkin   +8 more
doaj   +1 more source

Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis [PDF]

, 2016
Neoplastic accumulation of mast cells in systemic mastocytosis (SM) associates with activating mutations in the receptor tyrosine kinase KIT. Constitutive activation of tyrosine kinase oncogenes has been linked to imbalances in oxidant/antioxidant ...
Bai, Yun, Bandara, Geethani, Beaven, Michael A., Desai, Avanti, Kim, Do-Kyun, Komarow, Hirsh, Kulinski, Joseph M., Metcalfe, Dean D., Olivera, Ana, Prussin, Calman, Schwartz, Lawrence B.   +10 more
core   +12 more sources

Review and Updates on Systemic Mastocytosis and Related Entities

Cancers, 2023
Simple Summary Mast cells are specialized immune cells that mediate allergic and anaphylactic reactions, among other immunologic functions. The accumulation of abnormal mast cells can give rise to various disorders that range in severity of symptoms and ...
Julie Y. Li, Christopher B Ryder, Hailing Zhang, Samuel G. Cockey, Elizabeth Hyjek, Lynn Moscinski, Elizabeth Sagatys, Jinming Song   +7 more
semanticscholar   +1 more source

Challenges in applying diagnostic criteria for systemic mastocytosis

Blood Advances, 2023
Systemic mastocytosis (SM), fi rst reported in 1949 1 and de fi ned by the World Health Organization (WHO) classi fi cation, 2 can be challenging to diagnose.
N. Boggs, Xiaoping Sun, J. Lyons, Jeremy C. McMurray, D. M. Rose, Eric M Pryor, D. Metcalfe, I. Maric   +7 more
semanticscholar   +1 more source

Skin and bones: systemic mastocytosis and bone

Endocrinology, Diabetes & Metabolism Case Reports, 2023
Summary We report the case of a 69-year-old female with systemic mastocytosis, diagnosed based on widespread pigmented papules and macules, elevated serum tryptase levels and confirmatory skin and bone marrow biopsy, on a background of osteoporosis. A CT
Mawson Wang, M. Seibel
semanticscholar   +1 more source

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Leukemia, 2022
Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm associated with poor overall survival (OS). This study (NCT04695431) compared clinical outcomes between patients with AdvSM treated with avapritinib in the Phase 1 EXPLORER (NCT0256198 ...
A. Reiter, J. Gotlib, I. Alvarez-Twose, D. Radia, J. Lübke, P. Bobbili, Aolin Wang, C. Norregaard, S. Dimitrijević, E. Sullivan, M. Louie-Gao, J. Schwaab, I. Galinsky, C. Perkins, W. Sperr, P. Sriskandarajah, A. Chin, S. Sendhil, M. Duh, P. Valent, D. DeAngelo   +20 more
semanticscholar   +1 more source

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes

Allergy. European Journal of Allergy and Clinical Immunology, 2022
Current diagnostic algorithms for systemic mastocytosis (SM) rely on the detection of KITD816V in blood to trigger subsequent bone marrow (BM) investigations.
Paula Navarro-Navarro, I. Alvarez-Twose, A. Pérez-Pons, Ana Henriques, A. Mayado, A. García-Montero, L. Sánchez-Muñoz, Óscar González-López, A. Matito, C. Caldas, M. Jara-Acevedo, A. Órfão   +11 more
semanticscholar   +1 more source

Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update

Cancers, 2022
Simple Summary In this article, we outline recent updates in systemic mastocytosis (SM) classification, including the bone marrow mastocytosis subtype; and discuss the mast cell leukemia subtype (acute or chronic), the rare variant of SM known as well ...
S. El Hussein, H. Chifotides, J. Khoury, S. Verstovsek, B. Thakral   +4 more
semanticscholar   +1 more source

Patient‐reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey

Cancer, 2022
Systemic mastocytosis (SM) is a rare clonal neoplasm driven by KIT D816V and other mutations. Data were collected from the patient perspective on disease burden and included an SM‐specific symptom assessment tool.
Ruben A. Mesa, E. Sullivan, David G. Dubinski, Brittany L. Carroll, Valerie M. Slee, Susan V. Jennings, C. Finnerty, Linda S Bohannon, S. Mathias, Betsy J Lahue, M. Castells   +10 more
semanticscholar   +1 more source